MX369117B - Antagonistas del receptor ep4 para el tratamiento de cancer. - Google Patents

Antagonistas del receptor ep4 para el tratamiento de cancer.

Info

Publication number
MX369117B
MX369117B MX2016008394A MX2016008394A MX369117B MX 369117 B MX369117 B MX 369117B MX 2016008394 A MX2016008394 A MX 2016008394A MX 2016008394 A MX2016008394 A MX 2016008394A MX 369117 B MX369117 B MX 369117B
Authority
MX
Mexico
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
treatment
Prior art date
Application number
MX2016008394A
Other languages
English (en)
Inventor
Take Yukinori
Koizumi Shinichi
Okumura Takako
Nonomura Kazuhiko
Original Assignee
Askat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc filed Critical Askat Inc
Publication of MX369117B publication Critical patent/MX369117B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención provee un medicamento para el tratamiento de cáncer, el cual causa una reducción del cáncer. Esta invención se relaciona con el uso de un compuesto el cual tiene actividades inhibidoras en contra el receptor de prostaglandina E2 (receptor EP4) y es representado por la siguiente formula general (I), (II), (III), o (IV), o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal para la fabricación de un medicamento para el tratamiento de cáncer. La invención se relaciona con un método para el tratamiento de cáncer que comprende administrar el compuesto o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal a humanos o animales. El compuesto o una sal farmacéuticamente aceptable de éste, o la composición farmacéutica pueden ser usadas en combinación con uno o más agentes activos secundarios. (ver Fórmulas).
MX2016008394A 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer. MX369117B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009104568 2009-04-22
JP2010015445 2010-01-27
PCT/JP2010/057114 WO2010123049A1 (ja) 2009-04-22 2010-04-22 癌治療のための選択的ｅｐ４受容体拮抗物質

Publications (1)

Publication Number Publication Date
MX369117B true MX369117B (es) 2019-10-28

Family

ID=43011165

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008394A MX369117B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2011011058A MX345032B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011011058A MX345032B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer.

Country Status (12)

Country Link
US (5) US8921391B2 (es)
EP (3) EP3431085B1 (es)
JP (1) JP5668219B2 (es)
KR (1) KR101575706B1 (es)
CN (2) CN102421429B (es)
BR (1) BRPI1014174B8 (es)
CA (1) CA2754702C (es)
ES (3) ES2698508T3 (es)
HK (2) HK1214763A1 (es)
MX (2) MX369117B (es)
RU (1) RU2563817C2 (es)
WO (1) WO2010123049A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2698508T3 (es) * 2009-04-22 2019-02-05 Askat Inc Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer
KR102535283B1 (ko) * 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
AU2019255196A1 (en) * 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
EP3820469A4 (en) * 2018-07-11 2022-04-13 Arrys Therapeutics, Inc. EP4 INHIBITORS AND USE THEREOF
CN113260363A (zh) * 2018-09-27 2021-08-13 阿瑞斯医疗有限公司 格拉普兰特(grapiprant)单位剂型
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
CN114206866A (zh) * 2019-06-11 2022-03-18 泰昂治疗公司 ***素e2受体4拮抗剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304318A (zh) * 1999-03-16 2001-07-18 东丽株式会社 ***素ep4受体作用药和治疗方法
ATE348608T1 (de) 1999-08-10 2007-01-15 Glaxo Group Ltd Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
EP1258473A4 (en) * 2000-02-22 2004-09-01 Ono Pharmaceutical Co BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
JP2005526107A (ja) 2002-04-16 2005-09-02 藤沢薬品工業株式会社 慢性拒絶反応を予防および／または処置するための医薬
EP1663979B1 (en) 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
BRPI0509993A (pt) * 2004-04-20 2007-10-16 Pfizer Prod Inc combinações compreendendo ligandos de alfa-2-delta
CN1950333A (zh) 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
WO2005105733A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
BRPI0608819B8 (pt) 2005-03-11 2021-05-25 Askat Inc formas cristalinas de um derivado de imidazol
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
ES2698508T3 (es) 2009-04-22 2019-02-05 Askat Inc Sustancia antagonista del receptor EP4 selectivo para el tratamiento del cáncer
KR101539436B1 (ko) 2013-12-30 2015-07-24 주식회사 효성 가스 절연 개폐기의 부분 방전 검출 장치

Also Published As

Publication number Publication date
US20120088723A1 (en) 2012-04-12
MX345032B (es) 2017-01-12
CN102421429B (zh) 2016-08-17
EP3431085B1 (en) 2023-10-11
EP2422779A4 (en) 2013-06-19
US20220073510A1 (en) 2022-03-10
US20200188367A1 (en) 2020-06-18
EP2422779B1 (en) 2016-01-06
ES2960438T3 (es) 2024-03-04
US9688674B2 (en) 2017-06-27
US20150111920A1 (en) 2015-04-23
HK1214763A1 (zh) 2016-08-05
ES2698508T3 (es) 2019-02-05
EP3431085C0 (en) 2023-10-11
EP3431085A1 (en) 2019-01-23
CA2754702C (en) 2016-06-07
HK1166700A1 (zh) 2012-11-09
US11840530B2 (en) 2023-12-12
CA2754702A1 (en) 2010-10-28
BRPI1014174A2 (pt) 2016-04-05
EP2965756B1 (en) 2018-10-10
US10947235B2 (en) 2021-03-16
CN105596320A (zh) 2016-05-25
BRPI1014174B8 (pt) 2021-05-25
US20170253595A1 (en) 2017-09-07
MX2011011058A (es) 2011-11-18
WO2010123049A1 (ja) 2010-10-28
JPWO2010123049A1 (ja) 2012-10-25
KR101575706B1 (ko) 2015-12-10
EP2422779A1 (en) 2012-02-29
KR20120096402A (ko) 2012-08-30
BRPI1014174B1 (pt) 2020-10-06
EP2965756A1 (en) 2016-01-13
JP5668219B2 (ja) 2015-02-12
RU2563817C2 (ru) 2015-09-20
US10611761B2 (en) 2020-04-07
US8921391B2 (en) 2014-12-30
ES2562814T3 (es) 2016-03-08
CN105596320B (zh) 2019-03-22
CN102421429A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PH12015501678A1 (en) Inhibitors of influenza viruses replication
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ602510A (en) Treatment of lupus nephritis using laquinimod
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
NZ563774A (en) Inhibitors of VEGF receptor and HGF receptor signaling
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2013012588A (es) Inhibidores de cinasa.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
TNSN07419A1 (en) Methods for treating drug resistant cancer
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
TNSN08506A1 (en) Substituted carboxamides
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia